Rezolute Shares Plunge 85% Following Failed Clinical Trial, Legal Investigation Launched
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: Globenewswire
- Stock Price Plunge: Rezolute, Inc. shares plummeted approximately 85-90% on December 11, 2025, dropping from around $10.94 to an intraday low of $0.90 due to disappointing results from its Phase 3 sunRIZE clinical trial, reflecting extreme investor disappointment in the company's prospects.
- Clinical Trial Failure: The trial failed to meet both primary and key secondary endpoints, with the highest dose showing no statistically significant reduction in hypoglycemia events compared to placebo, leading to a significant decline in market confidence regarding its lead drug candidate.
- Legal Investigation Initiated: Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, encouraging investors who suffered significant losses to reach out, indicating that legal risks may further exacerbate the company's financial pressures.
- Severe Market Reaction: The stock's volatility led to a trading halt by Nasdaq under its volatility controls, which not only undermines investor confidence but may also pose greater challenges for the company in terms of financing and future development.
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 16.14 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.190
Low
12.00
Averages
16.14
High
20.00
Current: 2.190
Low
12.00
Averages
16.14
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
